DIMDNA

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 11 Mar 2025 filing date already counts against anyone who files later.

Record

Serial number

99078272

Mark type

Stylized text

Filed

11 Mar 2025

Published for opposition

06 Jan 2026

Attorney of record

Dustin Luettgen

Goods and services

• Class 001 — Chemicals: Chemical preparations, enzymes and DNA for the preparation of nucleic acids for scientific and industrial purposes; chemicals for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; linear nucleic acids for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; single stranded nucleic acids for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; single and double-stranded nucleic acids for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; aptamers for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; enzymes for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; DNA extracts and cassettes for scientific, industrial, and research use; DNA extracts being active chemical ingredients for use in the manufacture of therapeutics, biotechnology products and nanotechnology products; chemical preparations in the nature of DNA extracts for use in therapeutic, biotechnology and nanotechnology research
• Class 005 — Pharmaceuticals: Pharmaceutical preparations for the diagnosis and treatment of human and veterinary genetics disease and genetic diseases treatable with a nucleic acid therapy; pharmaceutical preparations for the prevention and treatment of genetic diseases; pharmaceutical preparations for human genetic medicines for treatment of genetic disease and genetic diseases treatable with a nucleic acid therapy; pharmaceutical preparations consisting of nucleic acid sequences, DNA extracts, and chemical reagents for medical use for treatment of genetic diseases and genetic diseases treatable with a nucleic acid therapy; therapeutic nucleic acid preparations for treatment of genetic diseases and genetic diseases treatable with a nucleic acid therapy; nucleic acid preparations having aptamers for medical or veterinary purposes; pharmaceutical preparations consisting of single stranded nucleic acids, DNA extracts and cassettes for treatment of genetic diseases and genetic diseases treatable with a nucleic acid therapy; pharmaceutical preparations consisting of single and double-stranded nucleic acids, DNA extracts and cassettes for treatment of genetic diseases and genetic diseases treatable with a nucleic acid therapy; pharmaceutical preparations consisting of linear nucleic acids, DNA extracts and cassettes for treatment of genetic diseases and genetic diseases treatable with a nucleic acid therapy; pharmaceutical preparations consisting of single and double-stranded nucleic acids, DNA extracts and cassettes for treatment of genetic diseases and genetic diseases treatable with a nucleic acid therapy; nucleic acid sequences and chemical reagents for medical and veterinary purposes; nucleic acids comprising natural and unnatural nucleotides for medical and veterinary purposes; nucleic acid analogues comprising synthetic backbones or a mixture of natural and synthetic backbones for medical and veterinary purposes; composites of nucleic acids or nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes; nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes in labeling, imaging and sensing applications; nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes in smart materials; two-dimensional and three-dimensional nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes in creating nanostructures and scaffolds
• Class 042 — Scientific and technological services: Scientific and technological services, namely, research and design in the field of nucleic acid research and development; chemical and biological analysis and research services; scientific research in the field of nucleic acids; scientific research and development in the field of creation of DNA extracts; scientific research, analysis, design and development relating to DNA based pharmaceutical drugs and therapies; scientific research and development in the fields of therapeutics, gene therapy, genetic medicines, diagnostics, biotechnology and nanotechnology; scientific research consultancy in the fields of therapeutics, gene therapy, genetic medicines, diagnostics, biotechnology, nanotechnology and DNA analysis

Owner

• SonoThera, Inc., South San Francisco, CA, US
• SonoThera, Inc., South San Francisco, CA, US

Prosecution history

• 03 Mar 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
• 06 Jan 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
• 06 Jan 2026 — PUBLISHED FOR OPPOSITION
• 31 Dec 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
• 09 Dec 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 09 Dec 2025 — EXAMINER'S AMENDMENT ENTERED
• 09 Dec 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
• 09 Dec 2025 — EXAMINERS AMENDMENT E-MAILED
• 09 Dec 2025 — EXAMINERS AMENDMENT -WRITTEN
• 11 Nov 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 11 Nov 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 11 Nov 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 14 Aug 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 14 Aug 2025 — NON-FINAL ACTION E-MAILED
• 14 Aug 2025 — NON-FINAL ACTION WRITTEN